PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

Abstract Background Multiple myeloma (MM) is a malignant plasma cell disease with a poor survival, characterized by the accumulation of myeloma cells (MMCs) within the bone marrow. Epigenetic modifications in MM are associated not only with cancer development and progression, but also with drug resi...

Full description

Bibliographic Details
Main Authors: Laurie Herviou, Alboukadel Kassambara, Stéphanie Boireau, Nicolas Robert, Guilhem Requirand, Carsten Müller-Tidow, Laure Vincent, Anja Seckinger, Hartmut Goldschmidt, Guillaume Cartron, Dirk Hose, Giacomo Cavalli, Jerome Moreaux
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Clinical Epigenetics
Subjects:
PRC2
Multiple myeloma
Predictive score
Epigenetics
Online Access:http://link.springer.com/article/10.1186/s13148-018-0554-4

Internet

http://link.springer.com/article/10.1186/s13148-018-0554-4

Similar Items